BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety
BD (NYSE: BDX) announced the European launch of the BD Surgiphor Surgical Wound Irrigation System on November 24, 2025. The device received CE approval and is now available in select European countries. Surgiphor is a sterile, pre-mixed, ready-to-use irrigation solution that uses a trusted antiseptic preservative to help loosen and remove debris and reduce bacterial load in surgical wounds. BD says the product is designed to simplify wound irrigation, reduce preparation time, and support evidence-based practices to help lower the risk of surgical site infections and improve surgical safety.
Availability is limited to select countries in Europe; healthcare providers should contact BD sales representatives for regional access and product details.
BD (NYSE: BDX) ha annunciato il lancio europeo del BD Surgiphor Surgical Wound Irrigation System il 24 novembre 2025. Il dispositivo ha ottenuto l'approvazione CE ed è ora disponibile in alcuni paesi europei. Surgiphor è una soluzione di irrigazione sterile, pre-miscelata, pronta all'uso che utilizza una conservante antisettica affidabile per facilitare l'allentamento e la rimozione dei detriti e ridurre la carica batterica nelle ferite chirurgiche. BD afferma che il prodotto è progettato per semplificare l'irrigazione delle ferite, ridurre i tempi di preparazione e supportare pratiche basate sull'evidenza per contribuire a diminuire il rischio di infezioni del sito chirurgico e migliorare la sicurezza chirurgica. La disponibilità è limitata a determinate nazioni europee; i fornitori di assistenza sanitaria dovrebbero contattare i rappresentanti di vendita BD per l'accesso regionale e i dettagli sul prodotto.
BD (NYSE: BDX) anunció el lanzamiento europeo del BD Surgiphor Surgical Wound Irrigation System el 24 de noviembre de 2025. El dispositivo recibió la aprobación CE y ya está disponible en ciertos países europeos. Surgiphor es una solución de irrigación estéril, premezclada y lista para usar que utiliza un conservante antiséptico confiable para ayudar a aflojar y eliminar residuos y reducir la carga bacteriana en las heridas quirúrgicas. BD dice que el producto está diseñado para simplificar la irrigación de las heridas, reducir el tiempo de preparación y apoyar prácticas basadas en la evidencia para ayudar a reducir el riesgo de infecciones del sitio quirúrgico y mejorar la seguridad quirúrgica. La disponibilidad está limitada a ciertos países de Europa; los proveedores de atención médica deben ponerse en contacto con los representantes de ventas de BD para obtener acceso regional y detalles del producto.
BD (NYSE: BDX)는 2025년 11월 24일에 BD Surgiphor Surgical Wound Irrigation System의 유럽 출시를 발표했습니다. 이 기기는 CE 인증을 받았으며 현재 일부 유럽 국가에서 사용 가능합니다. Surgiphor는 소독제가 신뢰받는 방부제인 멸균된, 미리 혼합된, 즉시 사용할 수 있는 세척 용액으로, 외상 부위의 이물질 제거와 박테리아 부하 감소를 돕습니다. BD는 이 제품이 상처 관개를 단순화하고 준비 시간을 줄이며 증거 기반의 실무를 지원하여 수술 부위 감염 위험을 낮추고 수술 안전을 향상시키도록 설계되었다고 말합니다. 이용 가능 여부는 유럽의 특정 국가에 한정되어 있습니다. 의료 제공자는 지역 접근성과 제품 세부 정보를 위해 BD 영업 담당자에게 문의해야 합니다.
BD (NYSE: BDX) a annoncé le lancement européen du BD Surgiphor Surgical Wound Irrigation System le 24 novembre 2025. Le dispositif a reçu l'approbation CE et est désormais disponible dans certains pays européens. Surgiphor est une solution d'irrigation stérile, prémélangée et prête à l'emploi qui utilise un conservateur antiseptique fiable pour aider à assouplir et à éliminer les débris et à réduire la charge bactérienne dans les plaies chirurgicales. BD indique que le produit est conçu pour simplifier l'irrigation des plaies, réduire le temps de préparation et soutenir des pratiques basées sur des preuves afin de réduire le risque d'infections du site opératoire et d'améliorer la sécurité chirurgicale. La disponibilité est limitée à certains pays d'Europe; les prestataires de soins doivent contacter les représentants commerciaux de BD pour accéder à la région et obtenir les détails du produit.
BD (NYSE: BDX) kündigte die Europäische Markteinführung des BD Surgiphor Surgical Wound Irrigation System am 24. November 2025 an. Das Gerät hat die CE-Zulassung erhalten und ist nun in ausgewählten europäischen Ländern erhältlich. Surgiphor ist eine sterile, vorgemischte, einsatzbereite Spüllösung, die ein zuverlässiges antiseptisches Konservierungsmittel verwendet, um Gewebeschutt zu lösen und zu entfernen und die bakterielle Kontamination in Operationswunden zu reduzieren. BD sagt, das Produkt sei darauf ausgelegt, die Wundspülung zu vereinfachen, die Vorbereitungszeit zu verkürzen und evidenzbasierte Praktiken zu unterstützen, um das Risiko von Infektionen der Operationsstelle zu senken und die chirurgische Sicherheit zu verbessern. Die Verfügbarkeit ist auf ausgewählte europäische Länder beschränkt; Gesundheitsdienstleister sollten BD-Vertriebsmitarbeiter kontaktieren, um regionalen Zugang und Produktdetails zu erhalten.
أعلنت BD (بورصة نيويورك: BDX) عن الإطلاق الأوروبي لـ BD Surgiphor Surgical Wound Irrigation System في 24 نوفمبر 2025. تم اعتماد الجهاز من CE وهو الآن متوفر في بعض الدول الأوروبية. Surgiphor هو محلول ريّ معقم، معبأ مسبقًا وجاهز للاستخدام يستخدم مادة حفظ مطهرة موثوقة للمساعدة في ارتخاء وإزالة الحطام وتقليل الحمولة البكتيرية في جروح الجراحة. تقول BD إن المنتج مصمم لتبسيط ري الجروح وتقليل وقت الإعداد ودعم الممارسات القائمة على الأدلة للمساعدة في تقليل مخاطر عدوى موقع الجراحة وتحسين سلامة الجراحة. التوفر محدود لعدد من الدول الأوروبية؛ يجب على مقدمي الرعاية الصحية الاتصال بممثلي مبيعات BD للوصول الإقليمي وتفاصيل المنتج.
- CE approval obtained for Surgiphor
- Product is sterile, pre-mixed and ready to use
- Antiseptic preservative included to reduce bacterial load
- Designed to reduce preparation time and simplify irrigation
- Availability limited to select European countries
Insights
BD launched the CE-approved BD Surgiphor™ in Europe, a sterile, ready-to-use wound irrigation system aimed at reducing bacterial load during surgery.
BD obtained Conformité Européenne (CE) approval and introduced BD Surgiphor™ in select European countries on
The commercial case rests on a few explicit facts: CE approval enables market entry in Europe, the sterile pre-mixed format removes on-site preparation, and the device is positioned to save preparation time and support evidence-based irrigation protocols. Key dependencies include hospital procurement decisions, clinical workflow adoption, and local availability in the stated "select European countries"; these determine uptake speed and operational impact. Watch for formal adoption milestones such as wider country rollouts, hospital procurement announcements, and any published clinical or real-world data on usage and infection-related outcomes over the next 6–18 months.
BD Surgiphor™ is a sterile, ready-to-use irrigation solution designed to help loosen and remove debris from surgical wounds during procedures. By flushing out debris and foreign materials, including microorganisms, it helps reduce the bacterial load that could lead to infection — a key factor associated with surgical site infections*1.
"This European launch marks a significant milestone in advancing surgical care," said Rian Seger, worldwide president of BD Surgery. "Surgical Site Infections are multifactorial and continue to present serious challenges to both patient outcomes and healthcare systems. Surgiphor™ supports clinicians in implementing evidence-based practices — such as surgical wound irrigation — to help reduce risk, enhance recovery, and improve overall surgical safety."
What makes Surgiphor™ different:
- It's pre-mixed and sterile, so hospitals don't need to prepare it before surgery1.
- It uses a trusted antiseptic as preservative in the solution to help reduce bacterial load that could lead to infection*1.
- The easy-to-handle design allows surgical teams to apply it quickly and precisely1.
By simplifying surgical wound irrigation and reducing preparation time, Surgiphor™ helps hospitals operate more efficiently while supporting safer outcomes for patients1. This launch reflects BD's ongoing commitment to advancing surgical care through practical, proven solutions that put patient safety first. For more information, contact your BD sales rep.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
* Surgical wound was in a simulated animal model
References: 1. BD data on file. Data generated in a preclinical model.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-surgiphor-surgical-wound-irrigation-system-expands-to-europe-to-help-hospitals-improve-patient-safety-302624084.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What did BD (BDX) announce on November 24, 2025 about Surgiphor in Europe?
How does BD Surgiphor claim to reduce surgical site infection risk for BD (BDX)?
Where can hospitals in Europe obtain BD Surgiphor (BDX) and when is it available?
What are the operational benefits BD (BDX) highlights for Surgiphor?
Does BD (BDX) claim clinical trial results for Surgiphor in the November 24, 2025 announcement?
